Over the past two decades, research has improved our understanding of the most common equine endocrine diseases: pituitary pars intermedia dysfunction (PPID, formerly referred to as Equine Cushing’s disease), and equine metabolic syndrome (EMS). One of the most critical new findings is that insulin dysregulation (ID) is the key driver of horses developing endocrinopathic laminitis, or now called hyperinsulinemia-associated laminitis (HAL), formerly referred to as founder. As we learn new information about these disorders, we continue to change the guidelines and recommendations for diagnostic testing. If a horse is suspected to have one of these endocrine disorders, timely and accurate diagnostic testing is key for developing a management and dietary plan to lower the risk of these horses developing laminitis. Diagnostic testing and outcomes are not a “one-size-fits-all” model, as there are different metabolic types. Thus, evaluating the complete picture, including both clinical signs of disease and diagnostic testing, is critical.

Brief Review of PPID, EMS and the involvement of ID

ID is the key feature and top concern for equids with EMS, and ID can coexist in equids with PPID. PPID is a progressive and debilitating disease affecting older horses of all breeds with a reported prevalence of more than 20% in horses older than 15 years and more than 25% in horses older than 20 years. PPID is characterized by abnormal growth and function of the pituitary gland in the pars intermedia region, causing abnormal secretion of various hormones.

This then contributes to the clinical signs seen with PPID, which can be varied and include hypertrichosis/hirsutism (overabundant hair growth and failure to shed hair), weight loss, abnormal fat redistribution, muscle wastage/atrophy, lethargy and depression, polyuria/polydipsia (increased drinking and urination) and increased susceptibility to infections such as sinusitis and hoof abscesses being most common.

Advertisement